IDEAYA Biosciences (IDYA) analyst forecast and price target
Analyst forecast
Consensus of 15 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Outperform | $60.00 from $58.00 | Aug 5, 2026 |
| Truist Securities | Maintained | Buy | $59.00 from $63.00 | Aug 5, 2026 |
| Truist Securities | Maintained | Buy | $63.00 from $65.00 | Jul 7, 2026 |
| RBC Capital | Maintained | Outperform | $48.00 from $53.00 | Jul 7, 2026 |
| Wedbush | Maintained | Outperform | $58.00 | Jun 12, 2026 |
| Wedbush | Maintained | Outperform | $58.00 | Jun 2, 2026 |
| Mizuho | Maintained | Outperform | $50.00 from $52.00 | May 7, 2026 |
| Guggenheim | Maintained | Buy | $54.00 from $50.00 | Apr 14, 2026 |
| Wedbush | Maintained | Outperform | $58.00 from $52.00 | Apr 14, 2026 |
| RBC Capital | Maintained | Outperform | $53.00 from $49.00 | Apr 14, 2026 |
| Wells Fargo | Maintained | Overweight | $48.00 from $44.00 | Apr 14, 2026 |
| Goldman Sachs | Maintained | Neutral | $35.00 from $31.00 | Apr 14, 2026 |
| Wedbush | Maintained | Outperform | $52.00 | Mar 31, 2026 |
| Citigroup | Maintained | Buy | $65.00 from $64.00 | Feb 19, 2026 |
| Wedbush | Maintained | Outperform | $52.00 from $49.00 | Feb 18, 2026 |
| Guggenheim | Maintained | Buy | $50.00 | Feb 18, 2026 |
| RBC Capital | Maintained | Outperform | $49.00 | Feb 18, 2026 |
| RBC Capital | Maintained | Outperform | $45.00 from $41.00 | Jan 21, 2026 |
| UBS | Initiated Coverage | Buy | $50.00 | Jan 7, 2026 |
| Truist Securities | Maintained | Buy | $60.00 from $59.00 | Jan 6, 2026 |
Frequently asked questions
What is the price target for IDYA stock?
The average 12-month analyst price target for IDEAYA Biosciences (IDYA) is $55.67, with a high estimate of $60.00 and a low of $48.00, across 3 analysts.
Is IDYA a buy, sell, or hold?
Analysts covering IDEAYA Biosciences currently average a Buy rating: 14 buy, 1 hold and 0 sell, from 15 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for IDYA?
The average price target of $55.67 implies 38.82% upside from the last price of $40.10.
What is the latest analyst rating on IDYA?
On Aug 5, 2026, Wedbush maintained IDEAYA Biosciences at Outperform with a price target of $60.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.